Literature DB >> 10600292

Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.

M Rintala1, P Inki, P Klemi, M Jalkanen, S Grénman.   

Abstract

OBJECTIVES: The expression of syndecan-1, a cell surface heparan sulfate proteoglycan, is reduced during malignant transformation of squamous cells. Studies on squamous cell carcinoma of the head and neck have shown that syndecan-1-positive tumors are associated with longer overall and recurrence-free survival. The purpose of this study was to analyze syndecan-1 expression in invasive cervical carcinoma and to examine the association of syndecan-1 expression with prognostic factors and overall survival.
METHODS: The study population consisted of 124 patients treated for primary invasive carcinoma of the uterine cervix at the Turku University Central Hospital during the years 1970-1988. The material consisted of 102 (82.3%) squamous cell carcinomas, 16 (12.9%) adenocarcinomas and 1 (0.8%) adenosquamous carcinoma, 1 (0.8%) small cell carcinoma, 1 (0. 8%) adenoid basal carcinoma, 1 (0.8%) carcinosarcoma, and 2 (1.6%) unclassified cervical carcinomas. Syndecan-1 expression was determined on paraffin-embedded tissue blocks using a human syndecan-1-specific monoclonal antibody B-B4 and immunohistochemistry. The expression of syndecan-1 was classified according to staining intensity as well as the percentage of positively stained tumor cells.
RESULTS: Staining intensity was strong in 44 (36%) samples, while 24 (19%) specimens remained syndecan-1-negative. In 49 (40%) samples, the percentage of syndecan-1-positive cells was >/=90%. Syndecan-1 expression, as determined by >/=50% positively stained tumor cells, was associated with the grade of differentiation (P = 0.03) and squamous histology (P < 0.001), but was not associated with clinical stage (P = 0.16) or disease-free survival (P = 0.86). Age (P = 0.003) and clinical stage (P < 0.001) were significant prognostic factors, but syndecan-1 expression determined neither by percentage of positively stained tumor cells nor by staining intensity was associated with the outcome.
CONCLUSIONS: In cervical carcinoma syndecan-1 is associated with histological differentiation grade and squamous histology, but does not predict clinical outcome. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600292     DOI: 10.1006/gyno.1999.5595

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia.

Authors:  Gábor Sobel; István Szabó; Csilla Páska; András Kiss; Ilona Kovalszky; Anna Kádár; Ferenc Paulin; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

2.  Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis.

Authors:  Yimin Xu; Jun Yuan; Ziheng Zhang; Lvbiao Lin; Shengliang Xu
Journal:  Mol Biol Rep       Date:  2012-06-20       Impact factor: 2.316

Review 3.  Targeting syndecan-1: new opportunities in cancer therapy.

Authors:  Zecheng Yang; Shuaitong Chen; Haoqiang Ying; Wantong Yao
Journal:  Am J Physiol Cell Physiol       Date:  2022-05-18       Impact factor: 5.282

Review 4.  New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells.

Authors:  Innoc Han; Haein Park; Eok-Soo Oh
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

5.  Prognostic significance of syndecan-1 expression in cervical cancers.

Authors:  Yu Im Kim; Ahwon Lee; Bum Hee Lee; Su Young Kim
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

Review 6.  Syndecans in tumor cell adhesion and signaling.

Authors:  DeannaLee M Beauvais; Alan C Rapraeger
Journal:  Reprod Biol Endocrinol       Date:  2004-01-07       Impact factor: 5.211

Review 7.  The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors.

Authors:  Tünde Szatmári; Katalin Dobra
Journal:  Front Oncol       Date:  2013-12-19       Impact factor: 6.244

Review 8.  Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Sathyen A Prabhu; Matthew Gliksman; Betty Tai; Ahmet Hatipoglu; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2015-10-06

Review 9.  Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysis.

Authors:  Hao-Tang Wei; Er-Na Guo; Bao-Guo Dong; Li-Sheng Chen
Journal:  BMC Gastroenterol       Date:  2015-10-30       Impact factor: 3.067

10.  The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.

Authors:  Bodil Fadnes; Oystein Rekdal; Lars Uhlin-Hansen
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.